Who Pays
Health economics, health technology assessment, reimbursement models, and insurance coverage for psychedelic therapies.
Regulatory approval opens the door, but reimbursement determines who walks through it. A therapy that is approved but not covered by insurance or national health systems remains inaccessible to the vast majority of patients. For psychedelic-assisted therapy — with its extended session times, specialized therapist requirements, and facility needs — the economics are particularly challenging.
Health technology assessment (HTA) bodies play a crucial gatekeeping role in many healthcare systems. Organizations like NICE in England, G-BA in Germany, HAS in France, and ICER in the United States evaluate whether new therapies offer sufficient value relative to their cost. These assessments typically rely on cost-effectiveness analyses that compare a therapy's outcomes (often measured in quality-adjusted life years, or QALYs) against its price and the cost of existing alternatives.
Early health economic modeling for psychedelic therapies suggests they could be cost-effective — even cost-saving — compared to standard treatments for conditions like treatment-resistant depression and PTSD. The logic is intuitive: if two or three psilocybin sessions can achieve durable remission, the long-term costs may be far lower than years of antidepressant prescriptions, therapy appointments, and the broader economic burden of untreated mental illness. But these models depend heavily on assumptions about durability of effect, retreatment rates, and the real-world cost of delivering therapy.
The pricing question is equally complex. Psychedelic-assisted therapy is expensive to deliver — a single psilocybin session might require 8+ hours of therapist time, plus preparation and integration sessions. Companies must set prices that cover these costs while remaining within the willingness-to-pay thresholds of HTA bodies and insurers. Some are exploring innovative pricing models, including outcomes-based contracts and value-based agreements.
In this section, we dive deep into the economics of psychedelic therapy implementation. We examine HTA processes across key markets, analyze the emerging cost-effectiveness evidence, explore different reimbursement models, and hear from health economists and payer representatives about what it will take to secure coverage. This is arguably the most critical — and least understood — piece of the implementation puzzle.
Articles
Payer Evidence Checklist for Psychedelic Therapies
What payers and HTA bodies need before psychedelic therapies can move from promising clinical evidence to coverage decisions.
The Personnel-Hours Question in Psychedelic Therapy
An evidence-first guide to supervised staff-hours in psychedelic therapy, and why protocol design, role mix, and regional systems shape cost and access.
Psychedelic Therapy Access in Europe: Comparison
Compare ketamine and esketamine licensing, reimbursement, and patient access pathways across selected European markets.
EU and UK HTA in 2026: Implications for reimbursement readiness
How EU HTA implementation and UK methods updates affect reimbursement strategy for psychedelic interventions.
Payer and Health Technology Assessments
Securing access to psychedelic therapies requires working with payers and health technology assessment (HTA) bodies after regulatory approval. These...
Reimbursement Landscape in Europe
In Europe, while the European Medicines Agency (EMA) handles drug approvals centrally for most countries, each country makes its own decisions about...
External Resources
Regulation (EU) 2021/2282 on health technology assessment
Joint EU HTA framework and timelines relevant to evidence strategy and payer readiness.
European Commission • 15 Dec 2021 • EU • Regulation • Reviewed 17 Apr 2026
Implementation of the Regulation on Health Technology Assessment
framework source relevant to who pays.
European Commission • 12 Jan 2025 • EU • Framework • Reviewed 17 Apr 2026
Guidance on reporting requirements for multiplicity issues and subgroup/sensitivity/post hoc analyses in joint clinical assessments
guidance source relevant to who pays.
European Commission (DG SANTE) • 1 Jan 2024 • EU • Guidance • Reviewed 17 Apr 2026
NICE health technology evaluations manual (PMG36)
guidance source relevant to who pays.
National Institute for Health and Care Excellence (NICE) • 31 Mar 2026 • UK • Guidance • Reviewed 17 Apr 2026
Guide to the methods of technology appraisal 2013 (PMG9)
guidance source relevant to who pays.
National Institute for Health and Care Excellence (NICE) • 4 Apr 2013 • UK • Guidance • Reviewed 17 Apr 2026
NICE real-world evidence framework (ECD9)
guidance source relevant to who pays.
National Institute for Health and Care Excellence (NICE) • 23 Jun 2022 • UK • Guidance • Reviewed 17 Apr 2026
NICE TA854: Esketamine nasal spray for treatment-resistant depression
Technology appraisal with commissioning implications for NHS pathway decisions.
National Institute for Health and Care Excellence (NICE) • 14 Dec 2022 • UK • Guidance • Reviewed 17 Apr 2026
G-BA resolution justification on Esketamine reassessment (D-930)
framework source relevant to who pays.
Federal Joint Committee (G-BA) • 21 Sept 2023 • Germany • Framework • Reviewed 17 Apr 2026
Pakketadvies esketamine neusspray (Spravato) bij therapieresistente depressie
framework source relevant to who pays.
Zorginstituut Nederland • 30 Sept 2020 • Netherlands • Framework • Reviewed 17 Apr 2026
Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg (versie 2024)
guidance source relevant to who pays.
Zorginstituut Nederland • 16 Jan 2024 • Netherlands • Guidance • Reviewed 17 Apr 2026
EFPIA Patients W.A.I.T. Indicator 2023 Survey
analysis source relevant to who pays.
European Federation of Pharmaceutical Industries and Associations (EFPIA) • 1 Jan 2024 • Europe • Analysis • Reviewed 17 Apr 2026
Healthcare expenditure statistics by function, provider and financing scheme
analysis source relevant to who pays.
Eurostat • 1 Nov 2024 • EU • Analysis • Reviewed 17 Apr 2026